Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival

BMC Cancer

Table 4 Cumulative effect analysis by the number of unfavorable genotypes in miRNA biogenesis pathway genes and disease free survival

Number of unfavorable genotypes	Disease-free survival
Number of unfavorable genotypes	Cases, N ^a (%)	Relapse, N (%)	aHR^b (95 % CI)	P
0-2	163 (35.4)	18 (21.4)	1 (reference)
3	188 (40.9)	32 (38.1)	2.16(1.18- 3.93)	1.22E-02
4-6	109 (23.7)	34 (40.5)	4.47(2.45- 8.14)	9.87E-07
P _trend			2.11(1.57- 2.83)	6.11E-07
	Overall survival
	Cases, N ^a (%)	Death, N (%)	aHR ^c (95 % CI)	P
0-2	6 (14.6)	124 (26.4)	1 (reference)
3	12 (29.3)	214 (45.5)	1.21(0.44- 3.30)	7.13E-01
4-5	23 (56.1)	132 (28.1)	5.34(2.12-13.49)	3.93E-04
P _trend			2.80(1.72- 4.55)	3.30E-05

NOTE Unfavorable genotypes were defined as rs2292779 (GG), rs11786030 (AG + GG), rs9606250 (AA + AT), rs1057035 (TC + CC), rs4759659 (GG + GA), and rs11060845 (TT) for disease-free survival and rs2292779 (GG), rs11786030 (AG + GG), rs1057035 (TC + CC), rs874332 (CC), and rs4968104 (TT) for overall survival, respectively.
^a Due to excluding the subject which has at least one missing genotype information in this analysis, all subjects are less than 480 for disease-free survival and 488 for overall survival.
^b Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), histologic grade (I-II and III), nuclear grade (I-II and III) and ER status (positive and negative), PR status (positive and negative) and hormone receptor therapy (yes and no).
^c Adjusted for age, tumor size (≤2 cm and >2 cm), lymph-node involvement (no and yes), metastasis (no and yes), histologic grade (I-II and III), and hormone receptor therapy (yes and no).

ISSN: 1471-2407